Table E2.
Characteristics at cohort entry of all individuals eligible for inclusion in the study population (before excluding individuals with a history of fracture)
| With atopic eczema (n = 526,808) | Without atopic eczema (n = 2,569,030) | |
|---|---|---|
| Total person-years of follow-up | 3,248,048 | 14,932,306 |
| Median follow-up time (IQR) | 5.0 (2.0-9.6) | 4.4 (1.7-8.9) |
| Female sex | 308,071 (58.5) | 1,489,261 (58.0) |
| Age band at entry (y) | ||
| 18-39 | 246,596 (46.8) | 1,217,722 (47.4) |
| 40-49 | 69,696 (13.2) | 351,927 (13.7) |
| 50-59 | 63,943 (12.1) | 329,007 (12.8) |
| 60-69 | 61,902 (11.8) | 303,790 (11.8) |
| ≥70 | 84,671 (16.1) | 366,584 (14.3) |
| Quintiles of IMD | ||
| 5 (most deprived) | 74,980 (14.2) | 370,200 (14.4) |
| 4 | 100,430 (19.1) | 489,144 (19.0) |
| 3 | 103,646 (19.7) | 508,469 (19.8) |
| 2 | 120,946 (23.0) | 589,313 (22.9) |
| 1 (least deprived) | 126,806 (24.1) | 611,904 (23.8) |
| Asthma diagnosis | 126,180 (24.0) | 318,433 (12.4) |
| BMI | ||
| Underweight (<18.5 kg/m2) | 37,756 (7.2) | 185,784 (7.2) |
| Normal weight (18.5-24.9 kg/m2) | 172,446 (32.7) | 828,367 (32.2) |
| Overweight (25.0-29.9 kg/m2) | 143,919 (27.3) | 667,277 (26.0) |
| Obese (≥30.0 kg/m2) | 92,507 (17.7) | 393,529 (15.3) |
| Missing | 80,180 (15.2) | 494,073 (19.2) |
| Harmful alcohol use | 14,438 (2.7) | 57,268 (2.2) |
| Smoking status | ||
| Nonsmokers | 266,134 (50.5) | 1,293,983 (50.4) |
| Current or former smokers | 246,782 (46.8) | 1,125,627 (43.8) |
| Missing | 13,892 (2.64) | 149,420 (5.82) |
| High-dose oral glucocorticoid prescription∗ | 93,443 (17.7) | 191,246 (7.4) |
All values are shown as numbers (percentages), unless otherwise stated.
IQR, Interquartile range.
∗
Prednisolone equivalent dose of 20 mg/day or more. Further details on variable definitions can be found in the Methods section in this article’s Online Repository.